Skip to main content
SpringerLink
Log in

Concurrent oral and inhalation drug delivery using a dual formulation system: the use of oral theophylline carrier with combined inhalable budesonide and terbutaline

  • Research Article
  • Published:
Drug Delivery and Translational Research Aims and scope Submit manuscript

Abstract

A novel approach to concurrently deliver oral and inhaled drugs as a single formulation is presented. A triple therapy containing theophylline (THEO; orally delivered) with budesonide (BUD) and terbutaline (TERB; as single and co-spray-dried inhaled powders) was prepared as an ordered mix, with THEO acting as a carrier. The aerosolisation performance of THEO formulations containing BUD and TERB alone, physical mix and co-spray-dried powder was evaluated using a next-generation impactor (NGI). Physicochemical properties were investigated using electron microscopy, laser diffraction, dynamic vapour sorption and thermal analysis. NGI analysis indicated that >99 % of the THEO powder was >4.46 μm, with >90 % dissolved within 5 min. Particle size analysis showed TEB and BUD samples were of a suitable size for inhalation. Thermal and moisture analysis suggested powders to be stable at room temperature up to 70 % RH. Aerosol studies indicated a different performance of BUD and TERB depending on the mixing procedure. The co-spray-dried formulation showed the highest performance, with a fine particle fraction (≤4.46 μm) of BUD and TERB of 34.39 ± 3.56 and 33.61 ± 5.67 %, respectively. Such observations suggest that this multicomponent drug delivery system could be developed to concomitantly deliver oral and inhaled drugs, an approach that, to date, does not exist. Ultimately, this technology potentially reduces the requirement for multiple therapies and increases patient compliance.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5
Fig. 6
Fig. 7
Fig. 8
Fig. 9
Fig. 10
Fig. 11
Fig. 12

Similar content being viewed by others

References

  1. Hambleton G, Weinberger M, Taylor J, Cavanaugh M, Ginchansky E, Godfrey S, et al. Comparison of cromoglycate (cromolyn) and theophylline in controlling symptoms of chronic asthma. A collaborative study. Lancet. 1977;1(8008):381–5.

    Article  CAS  PubMed  Google Scholar 

  2. Nassif EG, Weinberger M, Thompson R, Huntley W. The value of maintenance theophylline in steroid-dependent asthma. N Engl J Med. 1981;304(2):71–5.

    Article  CAS  PubMed  Google Scholar 

  3. Dusdieker L, Green M, Smith GD, Ekwo EE, Weinberger M. Comparison of orally administered metaproterenol and theophylline in the control of chronic asthma. J Pediatr. 1982;101(2):281–7.

    Article  CAS  PubMed  Google Scholar 

  4. Milgrom H, Bender B. Current issues in the use of theophylline. Am Rev Respir Dis. 1993;147(6 Pt 2):S33–9.

    Article  CAS  PubMed  Google Scholar 

  5. Vaz Fragoso CA, Miller MA. Review of the clinical efficacy of theophylline in the treatment of chronic obstructive pulmonary disease. Am Rev Respir Dis. 1993;147(6 Pt 2):S40–7.

    Article  CAS  PubMed  Google Scholar 

  6. Barnes PJ. Theophylline in chronic obstructive pulmonary disease: new horizons. Proc Am Thorac Soc. 2005;2(4):334–9. discussion 40–1.

    Article  CAS  PubMed  Google Scholar 

  7. Mellis CM, Peat JK, Woolcock AJ. The cost of asthma: can it be reduced? PharmacoEconomics. 1993;3(3):205–19.

    Article  CAS  PubMed  Google Scholar 

  8. Spector S. Noncompliance with asthma therapy—are there solutions? J Asthma. 2000;37(5):381–8.

    Article  CAS  PubMed  Google Scholar 

  9. Djukanovic R, Finnerty JP, Lee C, Wilson S, Madden J, Holgate ST. The effects of theophylline on mucosal inflammation in asthmatic airways: biopsy results. Eur Respir J. 1995;8(5):831–3.

    CAS  PubMed  Google Scholar 

  10. Rabe KF, Magnussen H, Dent G. Theophylline and selective PDE inhibitors as bronchodilators and smooth muscle relaxants. Eur Respir J. 1995;8(4):637–42.

    CAS  PubMed  Google Scholar 

  11. Markham A, Faulds D. Theophylline. A review of its potential steroid sparing effects in asthma. Drugs. 1998;56(6):1081–91.

    Article  CAS  PubMed  Google Scholar 

  12. Rabe KF, Dent G. Theophylline and airway inflammation. Clin Exp Allergy. 1998;28 Suppl 3:35–41.

    CAS  PubMed  Google Scholar 

  13. Tomita K, Chikumi H, Tokuyasu H, Yajima H, Hitsuda Y, Matsumoto Y, et al. Functional assay of NF-kappaB translocation into nuclei by laser scanning cytometry: inhibitory effect by dexamethasone or theophylline. Naunyn Schmiedebergs Arch Pharmacol. 1999;359(4):249–55.

    Article  CAS  PubMed  Google Scholar 

  14. Ohta K, Sawamoto S, Nakajima M, Kubota S, Tanaka Y, Miyasaka T, et al. The prolonged survival of human eosinophils with interleukin-5 and its inhibition by theophylline via apoptosis. Clin Exp Allergy. 1996;26 Suppl 2:10–5.

    Article  CAS  PubMed  Google Scholar 

  15. Yasui K, Hu B, Nakazawa T, Agematsu K, Komiyama A. Theophylline accelerates human granulocyte apoptosis not via phosphodiesterase inhibition. J Clin Invest. 1997;100(7):1677–84.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  16. American Thoracic Society (1995) Standards for the diagnosis and care of patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 152(5 Pt 2):S77–121.

    Google Scholar 

  17. Ram FS, Jones PW, Castro AA, De Brito JA, Atallah AN, Lacasse Y, et al. Oral theophylline for chronic obstructive pulmonary disease. Cochrane Database Syst Rev. 2002;4:CD003902.

    PubMed  Google Scholar 

  18. Zhou Y, Wang X, Zeng X, Qiu R, Xie J, Liu S, et al. Positive benefits of theophylline in a randomized, double-blind, parallel-group, placebo-controlled study of low-dose, slow-release theophylline in the treatment of COPD for 1 year. Respirology. 2006;11(5):603–10 (Randomized controlled trial. Research support, non-U.S. Government).

    Article  PubMed  Google Scholar 

  19. Prowse K, Walters EH. Can aminophylline reduce the need for oral corticosteroids? J Int Med Res. 1979;7 Suppl 1:101–5.

    PubMed  Google Scholar 

  20. Rivington RN, Boulet LP, Cote J, Kreisman H, Small DI, Alexander M, et al. Efficacy of Uniphyl, salbutamol, and their combination in asthmatic patients on high-dose inhaled steroids. Am J Respir Crit Care Med. 1995;151(2 Pt 1):325–32.

    Article  CAS  PubMed  Google Scholar 

  21. Lim S, Tomita K, Caramori G, Jatakanon A, Oliver B, Keller A, et al. Low-dose theophylline reduces eosinophilic inflammation but not exhaled nitric oxide in mild asthma. Am J Respir Crit Care Med. 2001;164(2):273–6.

    Article  CAS  PubMed  Google Scholar 

  22. Evans DJ, Taylor DA, Zetterstrom O, Chung KF, O’Connor BJ, Barnes PJ. A comparison of low-dose inhaled budesonide plus theophylline and high-dose inhaled budesonide for moderate asthma. N Engl J Med. 1997;337(20):1412–8.

    Article  CAS  PubMed  Google Scholar 

  23. Ukena D, Harnest U, Sakalauskas R, Magyar P, Vetter N, Steffen H, et al. Comparison of addition of theophylline to inhaled steroid with doubling of the dose of inhaled steroid in asthma. Eur Respir J. 1997;10(12):2754–60.

    Article  CAS  PubMed  Google Scholar 

  24. Morali T, Yilmaz A, Erkan F, Akkaya E, Ece F, Baran R. Efficacy of inhaled budesonide and oral theophylline in asthmatic subjects. J Asthma. 2001;38(8):673–9.

    Article  CAS  PubMed  Google Scholar 

  25. Dahl R, Larsen BB, Venge P. Effect of long-term treatment with inhaled budesonide or theophylline on lung function, airway reactivity and asthma symptoms. Respir Med. 2002;96(6):432–8.

    Article  CAS  PubMed  Google Scholar 

  26. Ford PA, Durham AL, Russell RE, Gordon F, Adcock IM, Barnes PJ. Treatment effects of low-dose theophylline combined with an inhaled corticosteroid in COPD. Chest. 2010;137(6):1338–44 (Randomized controlled trial. Research support, non-U.S. Government).

    Article  CAS  PubMed  Google Scholar 

  27. Wang Y, Lin K, Wang C, Liao X. Addition of theophylline or increasing the dose of inhaled corticosteroid in symptomatic asthma: a meta-analysis of randomized controlled trials. Yonsei Med J. 2011;52(2):268–75 (Meta-analysis).

    Article  PubMed  PubMed Central  Google Scholar 

  28. Todd G, Acerini C, Buck J, Murphy N, Ross-Russell R, Warner J. Acute adrenal crisis in asthmatics treated with high-dose fluticasone propionate. Eur Respir J. 2002;19:1207–9.

    Article  CAS  PubMed  Google Scholar 

  29. Adams N, Bestall J, Jones P. Inhaled fluticasone propionate for chronic asthma. Cochrane Library. 2002(1).

  30. Marlin GE, Hartnett BJ, Berend N, Hacket NB. Assessment of combined oral theophylline and inhaled beta-adrenoceptor agonist bronchodilator therapy. Br J Clin Pharmacol. 1978;5((1):45–50 (Clinical trial comparative study randomized controlled trial).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  31. Angus R, Reagon R, Cheesbrough A. Short-acting beta 2-agonist and oral corticosteroid use in asthma patients prescribed either concurrent beclomethasone and long-acting beta 2-agonist or salmeterol/fluticasone propionate combination. Int J Clin Pract. 2005;59(2):156–62.

    Article  CAS  PubMed  Google Scholar 

  32. Bateman ED, Boushey HA, Bousquet J, Busse WW, Clark TJ, Pauwels RA, et al. Can guideline-defined asthma control be achieved? The gaining optimal asthma control study. Am J Respir Crit Care Med. 2004;170(8):836–44. (Clinical trial multicenter study randomized controlled trial. Research support, non-U.S. Government].

    Article  PubMed  Google Scholar 

  33. O'Byrne PM, Bisgaard H, Godard PP, Pistolesi M, Palmqvist M, Zhu Y, et al. Budesonide/formoterol combination therapy as both maintenance and reliever medication in asthma. Am J Respir Crit Care Med. 2005;171(2):129–36 (Clinical trial multicenter study randomized controlled trial).

    Article  PubMed  Google Scholar 

  34. Pauwels RA, Lofdahl CG, Postma DS, Tattersfield AE, O'Byrne P, Barnes PJ, et al. Effect of inhaled formoterol and budesonide on exacerbations of asthma. Formoterol and Corticosteroids Establishing Therapy (FACET) International Study Group. N Engl J Med. 1997;337(20):1405–11 (Clinical trial multicenter study randomized controlled trial. Research support, Non-U.S. Government).

    Article  CAS  PubMed  Google Scholar 

  35. Society BT (2011) Scottish Intercollegiate Guidelines Network British Guideline on the Management of Asthma. http://www.brit-thoracic.org.uk/guidelines.aspx. 20 August 2012.

  36. Global Initiative for Asthma G (2011) Global strategy for asthma management and prevention. http://www.ginasthma.org/Guidelines/guidelines-resources.html. Accessed 20 August 2012.

  37. Hartnett BJ, Marlin GE. Comparison of oral theophylline and salbutamol by inhalation in asthmatic patients. Br J Clin Pharmacol. 1976;3(4):591–4 (Comparative study randomized controlled trial).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  38. Ward G, Schultz R (inventors) (2001) Pharmaceutical formulation and method for pulmonary and oral therapy, 19 July 2001.

  39. Islam N, Rashid A, Camm G (2011) Effects of magnesium stearate on the efficient dispersion of salbutamol sulphate from carrier-based dry powder inhaler formulations. Proceedings of RDD Europe 2011, volume II: Respiratory Drug Delivery (RDD) Online, Virginia Commonwealth University; 2011. p. 415–8.

  40. Guchardi R, Frei M, John E, Kaerger JS. Influence of fine lactose and magnesium stearate on low dose dry powder inhaler formulations. Int J Pharm. 2008;348(1–2):10–7. doi:10.1016/j.ijpharm.2007.06.041.

    Article  CAS  PubMed  Google Scholar 

  41. Frijlink HW, De Boer AH. Dry powder inhalers for pulmonary drug delivery. Expert Opin Drug Deliv. 2004;1(1):67–86 (Review).

    Article  CAS  PubMed  Google Scholar 

  42. Pharmacopoeia B. Consistency of formulated preparations. 2011.

  43. Pharmacopoeia US. Uniformity of dosage units. 2011.

  44. Amidon GL, Lennernas H, Shah VP, Crison JR. A theoretical basis for a biopharmaceutic drug classification: the correlation of in vitro drug product dissolution and in vivo bioavailability. Pharm Res. 1995;12(3):413–20 (In vitro research. Support, U.S. Government, P.H.S.).

    Article  CAS  PubMed  Google Scholar 

  45. Dressman JB, Amidon GL, Reppas C, Shah VP. Dissolution testing as a prognostic tool for oral drug absorption: immediate release dosage forms. Pharm Res. 1998;15(1):11–22 (Review. Research support, U.S. Government, P.H.S.).

    Article  CAS  PubMed  Google Scholar 

  46. Patton JS, Byron PR. Inhaling medicines: delivering drugs to the body through the lungs. Nat Rev Drug Discov. 2007;6(1):67–74 (Review).

    Article  CAS  PubMed  Google Scholar 

  47. Boraey MA, Hoe S, Sharif H, Miller DP, Lechuga-Ballesteros D, Vehring R. Improvement of the dispersibility of spray-dried budesonide powders using leucine in an ethanol–water cosolvent system. Powder Technology. 2013;236:171–8.

    Article  CAS  Google Scholar 

  48. Thi TH, Danede F, Descamps M, Flament MP. Comparison of physical and inhalation properties of spray-dried and micronized terbutaline sulphate. Eur J Pharm Biopharm: Off J Arbeitsgemeinschaft Pharm Verfahrenstechnik eV. 2008;70(1):380–8 (Comparative study).

    Article  CAS  Google Scholar 

  49. Borgstrom L, Bondesson E, Moren F, Trofast E, Newman SP. Lung deposition of budesonide inhaled via Turbuhaler®—a comparison with terbutaline sulfate in normal subjects. Eur Respir J. 1994;7(1):69–73.

    Article  CAS  PubMed  Google Scholar 

  50. GenomeQuest I. Terbutaline. 2005. http://www.drugbank.ca/drugs/DB00871. Accessed 17 August 2012.

  51. Shekunov BY, Chattopadhyay P, Tong HH, Chow AH. Particle size analysis in pharmaceutics: principles, methods and applications. Pharm Res. 2007;24(2):203–27 (Review. Research support, non-U.S. Government).

    Article  CAS  PubMed  Google Scholar 

  52. Hersey JA. Ordered mixing—new concept in powder mixing practice. Powder Technol. 1975;11(1):41–4.

    Article  Google Scholar 

  53. Pharmacopeia U. Uniformity of dosage units: content uniformity (905). In: Pharmacopeia U, editor; 2004. p. 2396–7.

  54. Thi THH, DanËde F, Descamps M, Flament M-P. Comparison of physical and inhalation properties of spray-dried and micronized terbutaline sulphate. Eur J Pharm Biopharm. 2008;70(1):380–8. doi:10.1016/j.ejpb.2008.04.002.

    Article  CAS  PubMed  Google Scholar 

  55. Suzuki E, Shimomura K, Sekiguchi K. Thermochemical study of theophylline and its hydrate. Chem Pharm Bull. 1989;37:493–7.

    Article  CAS  Google Scholar 

  56. Vora KL, Buckton G, Clapham D. The use of dynamic vapour sorption and near infra-red spectroscopy (DVS-NIR) to study the crystal transitions of theophylline and the report of a new solid-state transition. Eur J Pharm Sci: Off J Eur Fed Pharm Sci. 2004;22(2–3):97–105 (Research support, non-U.S. Government).

    Article  CAS  Google Scholar 

  57. Phadnis NV, Suryanarayanan R. Polymorphism in anhydrous theophylline—implications on the dissolution rate of theophylline tablets. J Pharm Sci. 1997;86(11):1256–63 (Research support, non-U.S. Government).

    Article  CAS  PubMed  Google Scholar 

  58. Nolan LM, Tajber L, McDonald BF, Barham AS, Corrigan OI, Healy AM. Excipient-free nanoporous microparticles of budesonide for pulmonary delivery. Eur J Pharm Sci. 2009;37(5):593–602.

    Article  CAS  PubMed  Google Scholar 

  59. The Merck Index (online resource). Whitehouse Station, NJ: Merck and Co., Inc. Accessed 23 August 2012.

  60. Harris RK, Hodgkinson P, Larsson T, Muruganantham A, Ymén I, Yufit DS, et al. Characterization of polymorphs and solvates of terbutaline sulfate. Cryst Growth Des. 2008;8(1):80–90.

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Respiratory Technology, Woolcock Institute of Medical Research, 431 Glebe Point Road, Glebe, NSW, 2037, Australia

    Rania O. Salama, Paul M. Young & Daniela Traini

  2. Discipline of Pharmacology, Sydney Medical School, University of Sydney, Sydney, NSW, 2006, Australia

    Paul M. Young & Daniela Traini

Authors
  1. Rania O. Salama
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Paul M. Young
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Daniela Traini
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Daniela Traini.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Salama, R.O., Young, P.M. & Traini, D. Concurrent oral and inhalation drug delivery using a dual formulation system: the use of oral theophylline carrier with combined inhalable budesonide and terbutaline. Drug Deliv. and Transl. Res. 4, 256–267 (2014). https://doi.org/10.1007/s13346-013-0137-z

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s13346-013-0137-z

Keywords

Search

Navigation